CMX157 decreased circulating levels of
tenofovir, lowered systemic exposure and reduced the potential for renal and
bone side effects."
Unfortunately, the reports by these financial advisors/reporters frequently lack the necessary precision. In this case the difference would be critical. I am not sure at this point what to trust, since in some presentations the company actually seemingly used simple Tenofovir, not TDF as a comparison drug.